

# Differences in the Modulation of Cortical Activity in Patients Suffering from Upper Arm Spasticity Following Stroke and Treated with Botulinum Toxin A

Rozdíly v modulaci kortikální aktivity u pacientů po cévní mozkové příhodě s reziduální spasticitou ruky léčených botulotoxinem A

## Abstract

**Aim:** The aim of our functional magnetic resonance (fMRI) study was to localize the changes of cerebral cortex activation in stroke patients suffering from upper limb spasticity and treated with botulinum toxin A (BoNT). **Materials and methodology:** 34 patients suffering from upper limb post-stroke spasticity were examined; 9 of these patients were grouped into two homogenous subgroups that allowed independent further analysis. Group A consisted of four patients (2 males, 2 females; aged  $25.5 \pm 3.4$  years, range 22–31 years) who suffered from hand plegia. Group B consisted of five patients (4 males, 1 female; aged  $67.0 \pm 11.1$  years, range 54–80) who were able to perform real finger movement. The change of arm spasticity was assessed by using the modified Ashworth scale (MAS). fMRI was performed during imaginary movement (group A) or real movement of the impaired hand (group B). fMRI sessions were performed before (W0) and four weeks (W4) after BoNT treatment. Group B underwent additional fMRI 11 weeks (W11) after BoNT application. **Results:** BoNT treatment decreased arm spasticity in all patients assessed 4 weeks following the BoNT injection. fMRI pre-BoNT treatment showed extensive and bilateral task-related activation of cortical areas. Following the BoNT treatment, temporary and partial shift towards normal distribution of activity occurred. The pre>post-BoNT contrast revealed a significant decrease in activation of the posterior cingulate/precuneus region (group A) and dorsolateral prefrontal cortex (group B). **Conclusion:** Our results imply that structures outside the traditional sensorimotor system may play a role in the relief of post-stroke spasticity.

## Souhrn

**Cíl:** Cílem naší fMR studie bylo lokalizovat změny aktivace mozkového kortexu u pacientů po cévní mozkové příhodě s reziduální spasticitou ruky léčených botulotoxinem A (BoNT). **Soubor a metodika:** Bylo vyšetřeno 34 pacientů po prodělané cévní mozkové příhodě s reziduální spasticitou ruky; z tohoto počtu vyšetřených byly nezávisle analyzovány dvě homogenní podskupiny. Skupina A byla tvořena 4 mladými pacienty (2 muži, 2 ženy, věk  $25 \pm 3,4$  let, rozptyl 22–31 let) s plegií ruky. Skupina B byla tvořena 5 staršími pacienty (4 muži, 2 ženy, věk  $67 \pm 11,1$  let, rozptyl 54–80) s parézou ruky. Mozkový motorický systém byl mapován pomocí funkční magnetické rezonance (fMR) během provádění motorické úlohy postiženou končetinou (skupina A: myšlený pohyb prstů; skupina B: skutečný pohyb prstů). Vyšetření bylo opakováno dvakrát, vždy před a čtyři týdny po aplikaci BoNT. Skupina B byla vyšetřena ještě potřetí s odstupem 11 týdnů od aplikace BoNT. Změna spasticity byla hodnocena pomocí modifikované Ashworthovy škály (MAS). **Výsledky:** Léčba BoNT snížila spasticitu u všech pacientů; hodnoceno čtyři týdny po aplikaci. fMR před aplikací BoNT ukazovalo abnormně rozsáhlou a bilaterální aktivaci korových oblastí během motorické úlohy. Po aplikaci BoNT došlo k dočasné a částečné normalizaci obrazu aktivace. Kontrast pre- > post-BoNT prokázal signifikantní snížení aktivace v zadním cingulu/precuneu (skupina A) a dorzolaterálním prefrontálním kortexu (skupina B). **Závěr:** Naše výsledky naznačují, že i struktury mimo klasický senzomotorický systém se uplatňují u postiktální spasticity.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

The Editorial Board declares that the manuscript met the ICMJE "uniform requirements" for biomedical papers.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

T. Veverka<sup>1</sup>, P. Hlustik<sup>1,2</sup>, P. Hok<sup>1</sup>, Z. Tomasova<sup>1</sup>, P. Otruba<sup>1</sup>, M. Kral<sup>1</sup>, Z. Tudos<sup>2</sup>, A. Krobot<sup>3</sup>, R. Herzig<sup>1</sup>, P. Kanovsky<sup>1</sup>

Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc:

<sup>1</sup> Department of Neurology

<sup>2</sup> Department of Radiology

<sup>3</sup> Department of Physiotherapy



Tomas Veverka, MD  
Department of Neurology  
Faculty of Medicine and Dentistry  
Palacký University  
and University Hospital  
I. P. Pavlova 6  
775 20 Olomouc  
e-mail: veverka.tomas@seznam.cz

Accepted for review: 28. 3. 2011

Accepted for print: 8. 2. 2013

## Key words

stroke – spasticity – functional magnetic resonance imaging – botulinum toxin

## Klíčová slova

cévní mozková příhoda – spasticita ruky – funkční magnetická rezonance – botulotoxin

This work was supported by the IGA Ministry of Health Czech Republic grant number NT13575-4/2012 and by institutional support of UH Olomouc.

## Introduction

Impairment of corticofugal tracts (tr. corticospinalis) in ischemic stroke leads to motor deficit presented by the majority of the surviving patients [1]. Up to two thirds of stroke survivors experience impaired function and spasticity of the upper limb [2]. A lesion in the sensory or motor circuits typically causes greater weakness of the wrist and fingers than proximal shoulder muscles [3]. Most of the motor function recovery or improvement occurs within 3–6 months post stroke and recovery is expected to plateau six mon-

ths post stroke [4]. Three recovery mechanisms are suggested [5]. Restitution includes processes that follow successful recanalisation of the occluded vessel and function restitution in the penumbra zone. Substitution includes processes likely related to brain plasticity [6–12]. Compensation comprises functional improvement achieved by modification of the movement pattern.

Brain plasticity means that the structure and function of the brain are continually reorganizing [13]. Reorganization of the sensory-motor maps is caused by affe-

rent inputs, i.e. interactions with the environment, its changes, learning etc. Brain plasticity after stroke is associated with substitution by undamaged areas in primary sensory and motor cortex and other cortical areas. Performance of an active motor task after stroke is associated with lateral and posterior displacement of activity in M1, probably into S1 [9,14]. The displacement occurs progressively over time in association with recovery of hand function [15].

The degree of muscle weakness is crucial in determining the degree of mo-

Tab. 1. Patient demographic characteristics.

Patient	Group	Sex	Age	Time post stroke (months)	Affected hand (side)	Severity of paresis	Number of fMRI sessions	Task
1		M	72	23	R	M	3	real
2	A	M	31	7	L	S	3	imagine
3	A	M	22	3	R	S	3	imagine
4	A	F	24	3	R	S	2	imagine
5	B	F	64	14	R	M	3	real
6		M	62	10	L	M	2	real
7		M	61	6	R	M	1	real
8	B	M	54	15	R	M	3	real
9		F	74	3	L	S	3	imagine
10		F	76	6	L	S	3	imagine
11		M	56	4	L	M	1	real
12		M	72	72	R	M	1	real
13		F	68	5	R	S	3	imagine
14	B	M	77	18	R	M	3	real
15	B	M	60	9	L	M	3	real
16		M	66	10	R	S	2	imagine
17		F	44	83	R	S	3	imagine
18		F	64	6	R	S	3	imagine
19	A	F	25	11	L	S	3	imagine
20		M	80	6	L	M	3	real/imagine
21		M	68	9	L	S	3	imagine
22	B	M	80	12	R	M	3	real
23		F	69	4	R	S	3	imagine
24		M	33	32	L	S	3	imagine
25		M	70	4	L	S	2	real
26		M	68	7	L	M	3	real
27		M	55	8	L	S	1	imagine
28		M	67	64	R	S	3	imagine
29		F	34	14	L	M	3	real
30		F	66	3	L	S	3	real
31		F	51	23	R	S	3	imagine
32		M	44	3	L	M	3	real
33		F	64	35	L	S	2	imagine
34		F	73	7	R	S	3	imagine

S – severe (unable to perform finger movement), M – mild (able to perform finger movement)

Tab. 2. Group A characteristics.

Patient No.	Sex	Age (years)	Lesion side	Lesion location	Hand dominance	Zung SDS index	MMSE	mMRC FE	mMRC FF	Barthel index
1	M	31	R	thalamus, capsule, BG	N	34	30	1-2	0	90
2	M	22	L	BG, capsule	D	30	29	0	0	85
3	F	24	L	thalamus, BG, capsule	D	44	30	1-2	1	90
4	F	25	R	thalamus, capsule, BG	N	54	29	0	0	80
<b>Summary</b>	<b>2M/2F</b>	<b>25.5 ± 3.4</b>	<b>2L/2R</b>	<b>heterogeneous</b>	<b>2D/2N</b>	<b>40.5 ± 10.8</b>	<b>29.5 ± 0.6</b>			<b>86.3 ± 4.8</b>

L – left, R – right, D – dominant hand impaired, N – non-dominant hand impaired, BG – basal ganglia, mMRC – modified MRC scale, FE – finger extensors, FF – finger flexors

vement deficit [16,17]. Other motor (especially spasticity) and non-motor (e.g. neglect, sensory impairment, emotional and speech-related difficulties) may also contribute. Spasticity frequently causes problems with common daily activities, hygiene, physical therapy, and nursing care [18]. A prospective study found spasticity prevalence to be 38% one year after stroke [19]. Focal spasticity is currently successfully treated with botulinum toxin [20,21].

There is growing evidence that BoNT treatment can relieve focal spasticity not only due to the peripheral site of action [22]. We hypothesized that besides the well-known neuromuscular junction site of action, BoNT treatment can relieve focal spasticity through dynamic changes at multiple levels of the motor system, presumably including the cerebral cortex. These processes should be reflected in changes of cortical activation during motor or mental tasks, as assessed using functional magnetic resonance imaging (fMRI).

The aim of our fMRI study was to localize the changes in cerebral cortex activation in stroke patients suffering from upper limb spasticity and treated with BoNT.

### Patients and methods

The study was approved by the institutional ethics committee and all subjects gave written consent for the study in accordance with the Helsinki Declaration.

A total of 34 patients who were in the chronic phase of ischemic stroke and manifesting with distal upper arm spasticity, were enrolled (tab. 1).

Four patients discontinued the study protocol and were excluded from further analysis. Twenty five patients underwent the complete protocol with 3 fMRI sessions; 5 patients underwent an incomplete protocol with 2 fMRI sessions. All enrolled patients suffered from unilateral distal arm weakness with spasticity following ischemic stroke at point 1+ or higher of the modified Ashworth scale (MAS). Exclusion criteria were the duration of post-stroke period less than 3 months, severe cognitive deficit and severe depression assessed using the MMSE and Zung scales [23,24], as these could alter participation in the study; and magnetic resonance imaging exclusion criteria.

Nevertheless, the whole group of enrolled patients was very heterogeneous. Patients differed in several characteristics, especially age, severity of neurological impairment and degree of spasticity. To obtain more homogeneous subgroups suitable for group analysis, we considered age and severity of neurological impairment as two main variables affecting both motor system plasticity and functional MRI task selection. Two subgroups that emerged using this classification were analyzed independently.

The first subgroup (group A) consisted of 4 young patients (2 males, 2 females; aged  $25.5 \pm 3.4$  years, range 22–31 years) who suffered from hand plegia (movement disability) and performed imagined finger movement as the functional MRI activation task [25]. The patients' characteristics are listed in tab. 2.

The second subgroup (group B) consisted of 5 elderly patients (4 males,

1 female; aged  $67.0 \pm 11.1$  years, range 54–80) who were able to perform real finger movement; this type of task allowed visual control and correction of finger movement. These patients also underwent an additional fMRI session 3 months following the BoNT application, when the effect on muscle fibers diminished [26]. The patients' characteristics are listed in tab. 3.

Patients were studied using a previously published protocol [25]. Spasticity was evaluated during clinical examination using the Modified Ashworth Scale [27]. The assessments were done at Week 0, when patients were screened, enrolled and injected with BoNT, then at Week 4, four weeks following the injection of BoNT (when BoNT effect is assumed to be maximal) and at Week 11 (only group B), 3 months after the BoNT injection, when the effect on muscle fibers ceased.

Similarly to behavioral assessments, functional MRI examinations were done at Week 0, Week 4 and Week 11 (only group B).

### Task

The task itself was a sequential finger movement or mental movement simulation in Roland's paradigm using the impaired hand. Patients with hand plegia (group A) first practiced the task with their healthy fingers and, when in the MRI scanner, they were asked to imagine performing the same movement with their impaired fingers. Patients with preserved movement of the impaired hand moved their fingers (in the sequential Roland's paradigm) under visual control of a technician.

Tab. 3. Group B characteristics.

Patient No.	Sex	Age (years)	Lesion side	Lesion location	Hand dominance	Zung SDS index	MMSE	mMRC FE	mMRC FF	Barthel index
1	M	54	L	thalamus, capsule, BG	D	31	24	3–4	4	85
2	M	60	R	BG, capsule	N	41	28	4	4–5	90
3	F	64	L	thalamus, capsule, BG	D	50	N/A	3–4	4	65
4	M	77	L	thalamus, capsule, BG	D	40	24	2–3	3	70
5	M	80	L	thalamus	D	49	N/A	3–4	4	20
<b>Summary</b>	<b>4M/1F</b>	<b>67.0 ± 11.1</b>	<b>4L/1R</b>	<b>hetero-geneous</b>	<b>4D/1N</b>	<b>42.2 ± 7.7</b>				<b>66.0 ± 27.7</b>

L – left, R – right, D – dominant hand impaired, N – non-dominant hand impaired, BG – basal ganglia, mMRC – modified MRC scale, FE – finger extensors, FF – finger flexors, N/A – not applicable – the MMSE score could not be interpreted because of the presence of expressive aphasia

In the MRI scanner, the task was performed with eyes closed, and the beginning and end of the active block were signalled verbally (start/stop) in MR-compatible headphones. The block paradigm timing was 15 s on (active task) – 15 s off (rest). Each experimental run consisted of 12 repetitions of the same task-rest block pairs, for a total of 6 minutes. Each participant had two experimental runs with the impaired hand.

### Treatment

The patients were treated with BoNT A injections into muscles of the affected arm at week 0. Treatment was injected using EMG guidance (Medtronic Keypoint, Alpine Biomed ApS, Denmark) and electrical muscle stimulation. The following muscles were always treated: the flexor carpi ulnaris muscle (FCU), the flexor carpi radialis muscle (FCR), the flexor digitorum superficialis muscle (FDS), and the flexor digitorum profundus muscle (FDP). When there was a need for additional injections into other muscles of the upper limb, they were injected using the same technique; the following muscles were injected: m. brachioradialis (BR) in one patient, m. biceps brachii (BB) in one patient, m. pronator teres (PT) in two patients. The dose of BoNT (Botox®) was 50 U (100 U in biceps brachii) per muscle. The effect of the BoNT treatment was tested using both clinical (MAS) and imaging assessments.

### Data acquisition

Magnetic resonance imaging data were acquired on 1.5 Tesla scanners (Avanto

and Symphony, Siemens, Erlangen, Germany) with a standard head coil. The MR imaging protocol covered the whole brain with 30 axial slices 5 mm thick, including anatomical T<sub>1</sub>-weighted images to provide an immediate overlay with functional data, fluid-attenuated inversion recovery (FLAIR) images to visualize brain lesions, functional T<sub>2</sub>\*-weighted (BOLD) images during task performance and rest, and a high-resolution 3D anatomical scan (MPRAGE). BOLD images were acquired with gradient echo EPI, TR/TE = 2,500/40 ms, FOV 220 mm, to provide 3.4 × 3.4 × 5 mm resolution. 144 images were acquired per each 6-minute functional run. A subject's head was immobilized with cushions to ensure maximum comfort and to minimize head movement.

### Analysis

fMRI data processing was carried out using FEAT (fMRI Expert Analysis Tool) Version 5.98, part of FSL (FMRIB's Software Library, [www.fmrrib.ox.ac.uk/fsl](http://www.fmrrib.ox.ac.uk/fsl)). The following pre-statistics processing was applied: motion correction using MCFLIRT [28]; slice-timing correction using Fourier-space time-series phase-shifting; non-brain removal using BET [29]; spatial smoothing using a Gaussian kernel of full width at half-maximum (FWHM) 10 mm; grand-mean intensity normalization of the entire 4D dataset by a single multiplicative factor; high-pass temporal filtering (Gaussian-weighted least-squares straight line fitting, with sigma = 15.0 s). Time-series statistical analysis was carried out

using FILM with local autocorrelation correction [30]. Registration to high resolution structural and/or standard space images was carried out using FLIRT [28,31].

Higher-level analysis was carried out using FLAME (FMRIB's Local Analysis of Mixed Effects) stage 1 and 2 with automatic outlier detection [32–34]. Z (Gaussianized T/F) statistic images were thresholded using a corrected cluster significance threshold of p = 0.05 [35]. In group B, the longitudinal 3-session design permits separation of the physiotherapy effects, expected to be gradually developing over time, from the transient effect of BoNT. The treatment effect at session 2 (W4) may be decomposed into a transient BoNT effect and a progressive effect of time and physiotherapy using specific post-hoc linear contrasts, comparing the weighted average of sessions 1 and 3 and session 2, using temporal distance from session 2 as the weights: (7 × S1 + 4 × S3)/11 versus S2.

### Results

#### Behavioral

BoNT treatment decreased arm spasticity across all patients measured 4 weeks following the BoNT injection.

In group A, the mean MAS scores were 3.5 (SD= .57) at Week 0, 1.38 (SD= .49) at Week 4 and the mean MAS change from baseline was 2.1 (P= .0013, one-sided paired t-test).

In group B, the mean MAS scores were 2.3 (SD= .67) at Week 0, 1.7 (SD= .27) at Week 4 and the mean MAS change from baseline was 0.6 (P= .0724, one-si-



ded paired t-test). In group B, the mean MAS score at Week 11 was 2.2 (SD= .45) and did not significantly differ from Week 0 (MAS change 0.1,  $p = 0.352$ , one-sided paired t-test).

### Imaging – group mean

Functional MRI during impaired hand movement or during imagined movement before BoNT treatment showed an extensive bilateral network of active areas, including the contralesional motor cortex, supplementary motor area, bilateral premotor cortices, bilateral superior parietal lobe, precuneus/posterior cingulate, bilateral basal ganglia and ipsilesional cerebellum (fig. 1a).

### Imaging – treatment effects

After the BoNT-treatment, both groups manifested reduction of previously widespread activation towards normal spatial distribution of activity into the midline and contralesional sensorimotor cortex (fig. 1b).


fMRI 11 weeks after the BoNT application (group B) showed a similar pattern of activation as the session prior to the BoNT treatment (fig. 1c).

In the group of patients with arm plegia (group A) the pre>post-BoNT contrast revealed a significant decrease ( $p < 0.05$ ) in activation of the posterior cingulate/precuneus region close to the midline, centered on the Montreal Neurological Institute (MNI) coordinates  $-8, -48, 0$  (fig. 2).

In the group of patients with preserved finger movement (group B), the pre>post-BoNT contrast revealed a significant decrease ( $p < 0.05$ ) in activation of the following contralesional cortical areas: dorsolateral prefrontal cortex, inferior frontal gyrus, and post-central gyrus (fig. 3). Local maxima for between-session contrast reflecting BoNT treatment effect in group B are shown in tab. 4.


### Discussion

Cerebral plasticity plays an important role in post-stroke recovery. Functional imaging studies showed that motor recovery is associated with massive recruitment of areas in the motor system early after the stroke. Initial increase in bilateral sensorimotor activity patterns normalize during recovery [36–39]. Alleviation of the extent and bilateral movement-related activity is




**Fig. 1. Functional MRI activation during a real finger movement (a) before BoNT treatment, (b) four and (c) eleven weeks following BoNT administration.**

Group mean statistical maps (Z-score) are overlaid in color on the MNI anatomical template. Right side of the brain is displayed on the left.



**Fig. 2.** BoNT treatment effect in group A: location, posterior cingulate/precuneus region of the most significant decrease of activation after BoNT treatment (group post-hoc contrast overlaid on an MNI anatomical template).

Right side of the brain is displayed on the left.



**Fig. 3.** BoNT treatment effect in group B: location, dorsolateral prefrontal cortex (DLPFC) of the most significant decrease of activation after BoNT treatment (group post-hoc contrast overlaid on the MNI anatomical template).

Right side of the brain is displayed on the left.

recovery-dependent: patients demonstrating poor motor recovery continue to activate a number of primary and non-primary motor regions more than those demonstrating good recovery [40,41].

Processes of cerebral plasticity may not be purely beneficial but can in fact even impair residual function (maladaptive plasticity) as reported in conditions such as dystonia, phantom limb pain and allodynia [42–45]. Development of spasticity after stroke may also be related to such maladaptive processes.

At present, BoNT is a well-established part of multimodal antispastic treatment. It has been proven that BoNT acts peripherally. However, there also is some evidence that BoNT acts through a supraspinal mechanism and can even affect cortical reorganization [21,46,47].

Most of the previous fMRI studies described changes in task-related cortical activity after specific rehabilitative treatment, e.g. constraint-induced therapy [41]. Only a few studies reported

cortical changes after BoNT injections into the spastic muscles [25,26,48].

In our research, we focused on the relationship between dynamic changes in movement-related brain activation and alleviation of spasticity induced by BoNT treatment.

In both our experiments, functional MRI examination done prior to the treatment showed widespread and bilateral activation during the motor task. The most significant regions of activation were found in the contralesional motor cortex, supplementary motor area, bilateral premotor cortices, bilateral superior parietal lobe, precuneus/posterior cingulate, bilateral basal ganglia and ipsilesional cerebellum. Imagery of finger movements (group A) evoked activation in the same cortical areas as those associated with performed movements (group B), similar to that shown previously [49].

We can assume that this pretreatment activation might be a uniform pattern of the lesioned brain as a form of maladaptation due to increased pathological proprioceptive afferentation (via Ia fibers) that is associated with spasticity.

As expected, BoNT-derived alleviation of spasticity was found in both groups and it was more prominent in the group of completely plegic patients with higher MAS before treatment. Also, the BoNT treatment-related reduction of abnormal

**Tab. 4.** Regions showing BOLD response changes related to BTX treatment in group B – significance of local maxima, MNI coordinates and atlas-based anatomical description.

Cluster Index	Z	x	y	z	Area (Harvard-Oxford Cortical Structural Atlas)
1	3.1	-40	44	20	„86% Frontal Pole, 1% Middle Frontal Gyrus“
1	3.09	-30	-30	74	„29% Postcentral Gyrus, 7% Precentral Gyrus“
1	3.09	-46	-54	58	„13% Angular Gyrus, 12% Supramarginal Gyrus, posterior division, 10% Lateral Occipital Cortex, superior division, 4% Superior Parietal Lobule“
1	3.08	-54	-42	52	„42% Supramarginal Gyrus, posterior division, 27% Supramarginal Gyrus, anterior division, 3% Superior Parietal Lobule, 2% Angular Gyrus“
1	3.06	-50	-48	54	„50% Supramarginal Gyrus, posterior division, 14% Angular Gyrus, 4% Superior Parietal Lobule, 3% Supramarginal Gyrus, anterior division, 1% Lateral Occipital Cortex, superior division“
1	3.06	-46	-42	62	„12% Superior Parietal Lobule, 8% Postcentral Gyrus, 1% Supramarginal Gyrus, anterior division“
1	2.93	-48	-22	62	„62% Postcentral Gyrus“
1	2.92	-46	-34	60	„52% Postcentral Gyrus, 6% Superior Parietal Lobule, 1% Supramarginal Gyrus, anterior division“
1	2.89	-30	-24	74	„24% Precentral Gyrus, 7% Postcentral Gyrus“
1	2.88	-30	-30	70	„59% Postcentral Gyrus, 15% Precentral Gyrus, 1% Superior Parietal Lobule“

extent and bilateral activation was observed in both groups. We extended the protocol of the first experiment by adding a third fMRI session (group B) at the time when BoNT effect on muscle fibers waned. BoNT-off data revealed a wide recruitment of cortical areas similar to that before the treatment. This approach allowed us to distinguish the BoNT-related effect from other mechanisms that could affect the results, e.g., spontaneous functional recovery or rehabilitation-related changes. In addition, all patients were in the chronic post-ischemic stroke stage, when activation patterns are stable [41].

In the periphery, BoNT affects intrafusal fibers as well as extrafusal ones and thus alters pathological sensory inputs to the CNS by blocking the neuromuscular junction of the gamma motor neurons. This blockade leads to a reduction of Ia afferent signals and indirectly inhibits the pre-existing feedback-driven execution mode [50]. This might be the mechanism through which the BoNT treatment reduces maladaptive plasticity. The hypothesis of central reorganization following BoNT treatment is supported by studies using neurophysiologic and imaging methods in patients with focal dystonia [51–53].

In both our experiments, decreased activation was found not only in the traditional motor regions but surprisingly also in regions that are not usual components of the motor system. The strongest hotspots were identified within the posterior cingulate cortex in group A and the dorsolateral prefrontal cortex (DLPFC) in group B.

The posterior cingulate (group A), consisting of Brodmann areas 29, 30, 23, and 31, is a component of the limbic system and has been associated with functions such as working memory, encoding of visuospatial tasks and extrapersonal space and global attention [54–56].

The posterior cingulate cortex has been frequently mentioned in connection with the default network [57]. The dorsolateral prefrontal cortex (group B) is thought to be an association area that includes parts of the superior and middle frontal gyrus, a minor portion of the inferior frontal gyrus in Brodmann areas 9 and 46 [58]. DLPFC has been associated with such functions as working memory, decision making and executive functions [59–61]. Both posterior cingulate and DLPFC also contribute to motor performance and

motor skill [62,63]. DLPFC has dense connections with cingulate cortices as was confirmed in previous studies [64,65].

On one hand, the localization of changes in both groups falls in the same functional category of “extended” motor system, i.e., areas that are not active during performance of common motor tasks but are related to either complex aspects of motor planning or adaption to extended motor skill learning or injury of motor structures. On the other hand, there are obvious differences between the groups. It is rational to associate them primarily with the basic differences between the groups, i.e., age and severity of paresis. We presume that motor control in the elderly patients with preserved voluntary hand movement resembles healthy subjects. DLPFC is a frontal association area, hierarchically superior to the premotor cortex and is activated in healthy subjects while planning and performing complex motor tasks, even though it has no direct connections to spinal motor neurons and acts through hierarchically lower premotor and motor areas. From this perspective, DLPFC is closer to the traditional cortical motor system (areas with corticospinal projections). On the other hand, the posterior cingulate/pre-cuneus area that manifested changes in the group of younger patients with hand plegia, is also mentioned in association with the motor system but at a qualitatively different level. This greater functional “distance” could be linked to inability to perform real voluntary hand movements in the presence of subcortical lesion of the corticospinal tract and, consequently, abnormal movement control. In such a situation, the motor network may engage anatomically and functionally more “distant” cortical areas. Unfortunately, these speculations are difficult to support with ancillary data as, for example, analogous studies in stroke patients with hand plegia treated for spasticity are presently unavailable. However, since both our pilot groups involved rather a small number of patients, the results should be interpreted with caution and generalization of our results to the whole clinical population is impossible. Nevertheless, we assume that the above mentioned areas may play a role in performing movement in situation when the traditional motor structures are engaged

in the processing of abnormal proprioceptive input from the spastic muscles of a paretic extremity.

## References

- Hendricks HT, van Limbeek J, Geurts AC, Zwartz MJ. Motor recovery after stroke: a systematic review of the literature. *Arch Phys Med Rehabil* 2002; 83(11): 1629–1637.
- Jørgensen HS, Nakayama H, Raaschou HO, Vive-Larsen J, Støier M, Olsen TS. Outcome and time course of recovery in stroke. Part I: Outcome. The Copenhagen Stroke Study. *Arch Phys Med Rehabil* 1995; 76(5): 399–405.
- Colebatch JG, Gandevia SC. The distribution of muscular weakness in upper motor neuron lesions affecting the arm. *Brain* 1989; 112(3): 749–763.
- Page SJ, Gater DR, Bach-Y-Rita P. Reconsidering the motor recovery plateau in stroke rehabilitation. *Arch Phys Med Rehabil* 2004; 85(8): 1377–1381.
- Dobkin BH, Carmichael TS. Principles of recovery after stroke. In: Barnes M, Dobkin B, Bogousslavsky J (eds). *Recovery after Stroke*. Cambridge: Cambridge University Press 2005.
- Weiller C, Chollet F, Friston KJ, Wise RJ, Frackowiak RS. Functional reorganization of the brain in recovery from striatocapsular infarction in man. *Ann Neurol* 1992; 31(5): 463–472.
- Ward NS, Brown MM, Thompson AJ, Frackowiak RS. Longitudinal changes in cerebral response to proprioceptive input in individual patients after stroke: an fMRI study. *Neurorehabil Neural Repair* 2006; 20(3): 398–405.
- Rijntjes M, Weiller C. Recovery of motor and language abilities after stroke: the contribution of functional imaging. *Prog Neurobiol* 2002; 66(2): 109–122.
- Calautti C, Baron JC. Functional neuroimaging studies of motor recovery after stroke in adults: a review. *Stroke* 2003; 34(6): 1553–1566.
- Bütefisch CM, Davis BC, Wise SP, Sawaki L, Kopylov L, Classen J et al. Mechanisms of use-dependent plasticity in the human motor cortex. *Proc Natl Acad Sci U S A* 2000; 97(7): 3661–3665.
- Rossini PM, Calautti C, Pauri F, Baron JC. Post-stroke plastic reorganization in the adult brain. *Lancet Neurol* 2003; 2(8): 493–502.
- Cramer SC. Functional imaging in stroke recovery. *Stroke* 2004; 35 (11 Suppl 1): 2695–2698.
- Pascual-Leone A, Amedi A, Fregni F, Merabet LB. The plastic human brain cortex. *Annu Rev Neurosci* 2005; 28: 377–401.
- Weiller C, Ramsay SC, Wise RJ, Friston KJ, Frackowiak RS. Individual patterns of functional reorganization in the human cerebral cortex after capsular infarction. *Ann Neurol* 1993; 33(2): 181–189.
- Jaillard A, Martin CD, Garambois K, Lebas JF, Hommel M. Vicarious function within the human primary motor cortex? A longitudinal fMRI stroke study. *Brain* 2005; 128(5): 1122–1138.
- Kamper DG, Fischer HC, Cruz EG, Rymer WZ. Weakness is the primary contributor to finger impairment in chronic stroke. *Arch Phys Med Rehabil* 2006; 87(9): 1262–1269.
- Ada L, O'Dwyer N, O'Neill E. Relation between spasticity, weakness and contracture of the elbow flexors and upper limb activity after stroke: an observational study. *Disabil Rehabil* 2006; 28(13–14): 891–897.
- Barnes MP. Medical management of spasticity in stroke. *Age Ageing* 2001; 30 (Suppl 1): 13–16.
- Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. *Clin Rehabil* 2002; 16(5): 515–522.



20. Ward AB, Aguilar M, De Beyl Z, Gedin S, Kanovsky P, Molteni F et al. Use of botulinum toxin type A in management of adult spasticity – a European consensus statement. *J Rehabil Med* 2003; 35(2): 98–99.
21. Rosales RL, Dressler D. On muscle spindles, dystonia and botulinum toxin. *Eur J Neurol* 2010; 17 (Suppl 1): 71–80.
22. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M et al. Long-distance retrograde effects of botulinum neurotoxin A. *J Neurosci* 2008; 28(14): 3689–3696.
23. Folstein MF, Folstein SE, McHugh PR. „Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975; 12(3): 189–198.
24. Zung WW. A self-rating depression scale. *Arch Gen Psychiatry* 1965; 12: 63–70.
25. Senkarova Z, Hlustik P, Otruba P, Herzig R, Kanovsky P. Modulation of cortical activity in patients suffering from upper arm spasticity following stroke and treated with botulinum toxin A: an fMRI study. *J Neuroimaging* 2010; 20(1): 9–15.
26. Tomasova Z, Hlustik P, Kral M, Otruba P, Herzig R, Krobot A et al. Cortical activation changes in patients suffering from post-stroke arm spasticity and treated with botulinum toxin A. *J Neuroimaging* 2011. DOI: 10.1111/j.
27. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. *Phys Ther* 1987; 67(2): 206–207.
28. Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. *Neuroimage* 2002; 17(2): 825–841.
29. Smith SM. Fast robust automated brain extraction. *Hum Brain Mapp* 2002; 17(3): 143–155.
30. Woolrich MW, Ripley BD, Brady M, Smith SM. Temporal autocorrelation in univariate linear modeling of fMRI data. *Neuroimage* 2001; 14(6): 1370–1386.
31. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. *Med Image Anal* 2001; 5(2): 143–156.
32. Beckmann CF, Jenkinson M, Smith SM. General multilevel linear modeling for group analysis in fMRI. *Neuroimage* 2003; 20(2): 1052–1063.
33. Woolrich MW, Behrens TE, Beckmann CF, Jenkinson M, Smith SM. Multilevel linear modelling for fMRI group analysis using Bayesian inference. *Neuroimage* 2004; 21(4): 1732–1747.
34. Woolrich M. Robust group analysis using outlier inference. *Neuroimage* 2008; 41(2): 286–301.
35. Worsley KJ. Statistical analysis of activation images. In: Jezzard P, Matthews PM, Smith SM (eds). *Functional MRI: an introduction to methods*. Oxford: Oxford University Press 2001: 251–270.
36. Small SL, Hlustik P, Noll DC, Genovese C, Solodkin A. Cerebellar hemispheric activation ipsilateral to the paretic hand correlates with functional recovery after stroke. *Brain* 2002; 125(7): 1544–1557.
37. Calautti C, Leroy F, Guincestre JY, Marié RM, Baron JC. Sequential activation brain mapping after subcortical stroke: changes in hemispheric balance and recovery. *Neuroreport* 2001; 12(18): 3883–3886.
38. Feydy A, Carlier R, Roby-Brami A, Bussel B, Cazalis F, Pierot L et al. Longitudinal study of motor recovery after stroke: recruitment and focusing of brain activation. *Stroke* 2002; 33(6): 1610–1617.
39. Marshall RS, Perera GM, Lazar RM, Krakauer JW, Constantine RC, DeLaPaz RL. Evolution of cortical activation during recovery from corticospinal tract infarction. *Stroke* 2000; 31(3): 656–661.
40. Ward NS, Brown MM, Thompson AJ, Frackowiak RS. Neural correlates of outcome after stroke: a cross-sectional fMRI study. *Brain* 2003; 126(6): 1430–1448.
41. Johansen-Berg H, Dawes H, Guy C, Smith SM, Wade DT, Matthews PM. Correlation between motor improvements and altered fMRI activity after rehabilitative therapy. *Brain* 2002; 125(12): 2731–2742.
42. Pujol J, Roset-Llobet J, Rosinés-Cubells D, Deus J, Narberhaus B, Valls-Solé J et al. Brain cortical activation during guitar-induced hand dystonia studied by functional MRI. *Neuroimage* 2000; 12(3): 257–267.
43. Flor H. Remapping somatosensory cortex after injury. *Adv Neurol* 2003; 93: 195–204.
44. Mäihöfner C, Handwerker HO, Birklein F. Functional imaging of allodynia in complex regional pain syndrome. *Neurology* 2006; 66(5): 711–717.
45. Kanovsky P. Dystonia: a disorder of motor programming or motor execution? *Mov Disord* 2002; 17(6): 1143–1147.
46. Kaňovský P, Streitová H, Daniel P, Hekerlová R, Bareš M, Dufek J. Dlouhodobá remise cervikální dystonie navozená léčbou botulotoxinem A – signál možného ovlivnění centrálního dystonického mechanismu? *Cesk Slov Neurol N* 1998; 61/94(2): 123–134.
47. Kanovsky P, Streitová H, Dufek J, Znojil V, Daniel P, Rektor I. Change in lateralization of the P22/N30 cortical component of median nerve somatosensory evoked potentials in patients with cervical dystonia after successful treatment with botulinum toxin A. *Mov Disord* 1998; 13(1): 108–117.
48. Manganotti P, Acler M, Formaggio E, Avesani M, Milanese F, Baraldo A et al. Changes in cerebral activity after decreased upper-limb hypertonus: an EMG-fMRI study. *Magn Reson Imaging* 2010; 28(5): 646–652.
49. Roth M, Decety J, Raybaudi M, Massarelli R, Delon-Martin C, Segebarth C et al. Possible involvement of primary motor cortex in mentally simulated movement: a functional magnetic resonance imaging study. *Neuroreport* 1996; 7(7): 1280–1284.
50. Rosales RL, Arimura K, Takenaga S, Osame M. Extracortical and intracortical muscle effects in experimental botulinum toxin-A injection. *Muscle Nerve* 1996; 19(4): 488–496.
51. Kanovsky P, Bares M, Streitova H, Klajblová H, Daniel P, Rektor I. Abnormalities of cortical excitability and cortical inhibition in cervical dystonia Evidence from somatosensory evoked potentials and paired transcranial magnetic stimulation recordings. *J Neurol* 2003; 250(1): 42–50.
52. Gelb DJ, Yoshimura DM, Olney RK, Lowenstein DH, Aminoff MJ. Change in pattern of muscle activity following botulinum toxin injections for torticollis. *Ann Neurol* 1991; 29(4): 370–376.
53. Ceballos-Baumann AO, Sheehan G, Passingham RE, Marsden CD, Brooks DJ. Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET study. *Brain* 1997; 120(4): 571–582.
54. Mesulam MM, Nobre AC, Kim YH, Parrish TB, Gitelman DR. Heterogeneity of cingulate contributions to spatial attention. *Neuroimage* 2001; 13(6): 1065–1072.
55. Bollinger J, Rubens MT, Zanto TP, Gazzaley A. Expectation-driven changes in cortical functional connectivity influence working memory and long-term memory performance. *J Neurosci* 2010; 30(43): 14399–14410.
56. Bledowski C, Rahm B, Rowe JB. What „works” in working memory? Separate systems for selection and updating of critical information. *J Neurosci* 2009; 29(43): 13735–13741.
57. Uddin LQ, Kelly AM, Biswal BB, Xavier Castellanos F, Milham MP. Functional connectivity of default mode network components: correlation, anticorrelation, and causality. *Hum Brain Mapp* 2009; 30(2): 625–637.
58. Rajkowska G, Goldman-Rakic PS. Cytoarchitectonic definition of prefrontal areas in the normal human cortex: II. Variability in locations of areas 9 and 46 and relationship to the Talairach Coordinate System. *Cereb Cortex* 1995; 5(4): 323–337.
59. Halsband U, Lange RK. Motor learning in man: a review of functional and clinical studies. *J Physiol Paris* 2006; 99(4–6): 414–424.
60. Galea JM, Albert NB, Ditye T, Miall RC. Disruption of the dorsolateral prefrontal cortex facilitates the consolidation of procedural skills. *J Cogn Neurosci* 2010; 22(6): 1158–1164.
61. Vanderhasselt MA, De Raedt R, Leyman L, Baeken C. Role of the left DLPFC in endogenous task preparation: experimental repetitive transcranial magnetic stimulation study. *Neuropsychobiology* 2010; 61(3): 162–168.
62. Jäncke L, Shah NJ, Peters M. Cortical activations in primary and secondary motor areas for complex bimanual movements in professional pianists. *Brain Res Cogn Brain Res* 2000; 10(1–2): 177–183.
63. Milton J, Solodkin A, Hlustik P, Small SL. The mind of expert motor performance is cool and focused. *Neuroimage* 2007; 35(2): 804–813.
64. Petrides M, Pandya DN. Dorsolateral prefrontal cortex: comparative cytoarchitectonic analysis in the human and the macaque brain and corticocortical connection patterns. *Eur J Neurosci* 1999; 11(3): 1011–1036.
65. Paus T, Castro-Alamancos MA, Petrides M. Cortico-cortical connectivity of the human mid-dorsolateral frontal cortex and its modulation by repetitive transcranial magnetic stimulation. *Eur J Neurosci* 2001; 14(8): 1405–1411.